Brief: Olema Oncology Q2 Net Income USD -30.382 Million
06/08/2024 21:02
Aug 06 (Reuters) - Olema Oncology Q2 operating expenses USD 33.53 million. * Q2 basic EPS USD -0.54 vs. IBES estimate USD -0.55 * Q2 income from operations USD -33.53 million
Recent news on Olema Pharmaceuticals
See all newsOlema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Brief: Olema Pharmaceuticals Q2 Net Income USD -63.2 Million
Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
Olema Pharmaceuticals Q1 net loss widens on higher R&D costs